Alk-Abello AS

4AJ0

Company Profile

  • Business description

    Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

  • Contact

    Boge Alle 6-8
    HorsholmDK-2970
    DNK

    T: +45 45747576

    E: [email protected]

    https://www.alk.net

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    2,759

Stocks News & Analysis

stocks

ASX healthcare share undervalued post earnings

Short term headwinds mask long term value opportunity.
stocks

ASX energy share sees 363% increase in dividend

Geopolitical tensions drive strong profit and dividends for oil refiner.
stocks

Wide moat share remains cheap despite rising costs

Higher costs weigh on profits but stronger sales trends support long term outlook.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,355.0038.30-0.41%
CAC 408,439.2013.81-0.16%
DAX 4026,266.14159.540.61%
Dow JONES (US)53,577.40160.240.30%
FTSE 10010,886.1631.840.29%
HKSE25,685.40174.300.68%
NASDAQ26,151.30171.110.66%
Nikkei 22566,328.13471.700.72%
NZX 50 Index14,051.4158.690.42%
S&P 5007,677.2824.420.32%
S&P/ASX 2009,146.2037.50-0.41%
SSE Composite Index3,916.8327.390.70%

Market Movers